Hilary Marston, M.D., M.P.H. Chief Medical Officer (CMO) of the FDA | Official Website
Hilary Marston, M.D., M.P.H. Chief Medical Officer (CMO) of the FDA | Official Website
This is a 66.7% decrease from the number of companies cited in the previous quarter.
Of the 19 citations issued, the most common citations include:
- You did not develop an FSVP.
- Procedures for corrective and preventive action have not been adequately established.
- Donor screening of HCT/P donors considered eligible indicated that the donor was not free of risk factors for infection due to communicable disease agents.
Most of the companies cited were involved in the Food and Cosmetics sector. The second most common type of company cited in the time period worked in the .
All of the companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Cheshni Foods, LLC | Food and Cosmetics | 11/17/2023 | Develop FSVP |
Cheshni Foods, LLC | Food and Cosmetics | 11/17/2023 | Very small importer assurances, supplier |
Conagra Brands, Inc. | Food and Cosmetics | 11/22/2023 | Identification - entry |
Fertility Centers of Illinois | Biologics | 10/18/2023 | Donor screening standards |
Fertility Centers of Illinois | Biologics | 10/18/2023 | Reasons for ineligibility on summary |
Fertility Centers of Illinois | Biologics | 10/18/2023 | Labeled re: biohazard, risks, test results |
FiMex, Inc. | Food and Cosmetics | 10/20/2023 | Develop FSVP |
Grafton Medical Alliance | Devices | 10/26/2023 | Lack of or inadequate procedures |
Grafton Medical Alliance | Devices | 10/26/2023 | Complaints |
Institute for Human Reproduction, School | Biologics | 10/25/2023 | Testing, screening, donor eligibility procedures |
Institute for Human Reproduction, School | Biologics | 10/25/2023 | Donor screening standards |
Institute for Human Reproduction, School | Biologics | 10/25/2023 | Statement re: certified testing lab |
Institute for Human Reproduction, School | Biologics | 10/25/2023 | Completion of eligibility determination |
Instrumed International, Inc. | Devices | 12/05/2023 | Document locations, Dissemination, etc. |
Instrumed International, Inc. | Devices | 12/05/2023 | Purchasing controls, Lack of or inadequate procedures |
Instrumed International, Inc. | Devices | 12/05/2023 | Product rework procedures, Lack of or inadequate procedures |
Instrumed International, Inc. | Devices | 12/05/2023 | Lack of or inadequate procedures |
Instrumed International, Inc. | Devices | 12/05/2023 | Documentation |
Vee Pak, LLC | Drugs | 12/11/2023 | Valid stability test methods |